Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
May 2, 2013
LONDON, 2 May, 2013 — Silence Therapeutics Plc, a leader in the discovery, development and delivery of novel RNA interference therapeutics for the treatment of serious diseases, has successfully raised £18.7 million of new funds. Covington & Burling advised Silence Therapeutics on the transaction. The Company expects to use the net proceeds of the placing of £18.7 million to fund a Phase Ib/IIa programme of Atu027, its most advanced internal drug candidate for the treatment of solid tumours, as well as to develop its non-cancer projects and broaden its clinical expertise. The London-based Covington team was led by corporate partner Natalie Walter with assistance from corporate associate Simon Williams.